Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business line and finalizes the date for its upcoming annual earnings release. The market anticipates the year-end report against a backdrop of high institutional ownership and a newly formed advisory board aimed at enhancing product development.

The company will provide a comprehensive look into its financial health on Tuesday, February 24, 2026. On that date, Orthofix is scheduled to disclose its results for the fourth quarter and the full fiscal year 2025. The release will occur before the formal opening of trading on U.S. exchanges.

Management will host a conference call to discuss the performance at Read more...